Quick Answer
Ernexa Therapeutics Inc. reported Total Assets of $5.83 million for the year ending 2025.
- Ernexa Therapeutics Inc. showed an increase of +10.7% in Total Assets from 2024 to 2025.
- This data is from Ernexa Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 13, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2011: $12.87 million | Q3 2011: $12.20 million | Q1 2012: $13.11 million | Q2 2012: $12.27 million | Q3 2012: $12.63 million | Q1 2013: $11.83 million | Q2 2013: $11.38 million | Q3 2013: $11.65 million | Q1 2014: $15.52 million | Q2 2014: $22.58 million | Q3 2014: $22.57 million | Q1 2015: $20.16 million | Q2 2015: $17.24 million | Q3 2015: $17.28 million | Q1 2016: $16.32 million | Q2 2016: $14.96 million | Q3 2016: $14.40 million | Q1 2017: $17.53 million | Q2 2017: $18.53 million | Q3 2017: $17.56 million | Q1 2018: $15.70 million | Q2 2018: $16.36 million | Q3 2018: $15.54 million | Q1 2019: $16.48 million | Q2 2019: $15.64 million | Q3 2019: $14.92 million | Q1 2020: $11.01 million | Q2 2020: $6.79 million | Q3 2020: $5.05 million | Q1 2021: $20.70 million | Q2 2021: $64.71 million | Q3 2021: $39.39 million | Q1 2022: $35.38 million | Q2 2022: $26.90 million | Q3 2022: $20.93 million | Q1 2023: $15.11 million | Q2 2023: $46.95 million | Q3 2023: $52.25 million | Q1 2024: $49.66 million | Q2 2024: $46.49 million | Q3 2024: $7.72 million | Q1 2025: $5.06 million | Q2 2025: $7.58 million | Q3 2025: $6.17 million.
- Over the full 16 years of available data (2010 to 2025), Ernexa Therapeutics Inc.'s Total Assets has declined by 55.6%.
- Historical annual values: Fiscal year 2025: $5.83 million | Fiscal year 2024: $5.27 million | Fiscal year 2023: $49.13 million | Fiscal year 2022: $22.28 million | Fiscal year 2021: $31.53 million | Fiscal year 2020: $13.78 million | Fiscal year 2019: $14.13 million | Fiscal year 2018: $14.86 million | Fiscal year 2017: $16.57 million | Fiscal year 2016: $16.70 million | Fiscal year 2015: $16.41 million | Fiscal year 2014: $22.27 million | Fiscal year 2013: $15.46 million | Fiscal year 2012: $12.66 million | Fiscal year 2011: $11.65 million | Fiscal year 2010: $13.13 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: